Data help define relationship between HPV, bladder cancer
“HPV6 positive serology was associated with an increased odds of bladder cancer, and I saw a trend in that it was younger patients with bladder cancer who had the HPV6 positivity,” says Lael S. Reinstatler, MD, MPH, in this video interview.
While previous research has shown a potential relationship between human papillomavirus (HPV) and bladder cancer, a recently reported study has more clearly defined this association.
At the Genitourinary Cancers Symposium in San Francisco, the authors of a study using a large, nationally representative database reported a significant association of HPV6 positive serology with a diagnosis of bladder cancer.
“HPV6 positive serology was associated with an increased odds of bladder cancer, and I saw a trend in that it was younger patients with bladder cancer who had the HPV6 positivity,” said first author Lael S. Reinstatler, MD, MPH, of Dartmouth Hitchcock Medical Center Lebanon, NH.
In this Urology Times video, Dr. Reinstatler describes the study’s unique methodology, other key findings, and the next steps in her group’s research.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
